GxP Conversations Podcast Ep 22: What Are Biosimilars? Development, Stability and Clinical Practice

What makes a biosimilar different from a conventional generic medicine? GxP Conversations Episode 22 explores biosimilar development, stability and clinical practice, with a focus on oncology and the quality systems supporting biological medicines. Need support with your own facility or quality system? W2 Cleanroom Consulting: https://www.w2cleanrooms.com We discuss how comparability with a reference biological medicine is assessed, why manufacturing and molecular complexity matter, and how stability, formulation and handling affect product quality. The conversation also considers immunogenicity, pharmacovigilance and communication with patients. In this episode: - Biological medicines, biosimilars and conventional generics. - Analytical comparability and manufacturing control. - Storage, cold-chain handling and stability considerations. - Immunogenicity, safety monitoring and confidence in clinical use. A biosimilar approved in the EU must demonstrate high similarity to its reference medicine without clinically meaningful differences in quality, safety or efficacy. That does not remove the need to follow the specific product's storage instructions, prescribing information and local clinical governance. This is an educational discussion for people working with biological medicines. Treatment, prescribing and switching decisions belong within the relevant clinical and pharmacy governance arrangements, not a general podcast description. #Biosimilars #BiologicalMedicines #PharmaceuticalQuality Free GxP app: www.whatisgxp.com Help Me GxP free training and resources: www.helpmegmp.com Help Me GxP is co-created and run by Kyle Winn and Adam Walker, who are also directors of W2 Cleanroom Consulting. W2 sponsors the channel. This video is for education. Use it alongside current guidance, your approved procedures and formal training.